Lung Cancer

A new inhibitor designed to target what’s been called an “undruggable” genetic mutation showed promising activity against advanced cancers with this mutation.

Changing the way individuals are selected to be screened for lung cancer could prevent 14% of lung cancer deaths per year.

In the first large, randomized trial to look at immunotherapy as a first-line cancer treatment, researchers found that adding the immunotherapy drug pembrolizumab to chemotherapy for advanced lung cancer led to better tumor control and overall survival than chemotherapy followed by pembrolizumab.

The update on the KEYNOTE-189 trial provides nearly two years data on use of the immunotherapy drug pembrolizumab in combination with platinum-based chemotherapy as a first-line treatment for metastatic non-small cell lung cancer.